Overview
Audry Kang is an Urologist in Largo, Maryland. Dr. Kang has been practicing medicine for over 10 years and is rated as an Experienced provider by MediFind in the treatment of Bladder Cancer. Her top areas of expertise are Stress Urinary Incontinence, Urinary Tract Infection in Children, Urinary Tract Infection (UTI), Cystectomy, and Ureteroscopy. Dr. Kang is currently accepting new patients.
Her clinical research consists of co-authoring 12 peer reviewed articles. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Bladder Cancer.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- MEDICARE MAPD
- MEDICARE SNP
- OTHER MEDICARE PART D
- PPO
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- EPO
- INSURANCE PLAN
- MEDICARE MAPD
- MEDICARE PDP
- OTHER COMMERCIAL
- OTHER MEDICARE
- PPO
- EPO
- HMO
- PPO
- MEDICARE MAPD
- OTHER MEDICARE
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- PPO
- HMO
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- EPO
- POS
- PPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- OTHER MEDICARE
- POS
- PPO
- OTHER MANAGED MEDICAID
- OTHER MEDICAID
- STATE MEDICAID
- EPO
- PPO
- PPO
- INSURANCE PLAN
- MEDICARE MAPD
- OTHER COMMERCIAL
- PPO
- EPO
- PPO
- EPO
- PPO
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
- HMO
- INSURANCE PLAN
- MEDICARE DISCOUNT CARD
- MEDICARE MAPD
Locations
1221 Mercantile Ln, Largo, MD 20774
110 Irving St Nw, Washington, DC 20010
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Johns Hopkins Outpatient Center
Dr. Max Kates is the R. Christian B. Evensen Professor and an associate professor of urology and oncology at the Brady Urological Institute at Johns Hopkins. He also directs the Division of Urologic Oncology for the Brady Urological Institute. Dr. Kates completed his undergraduate degree at Wesleyan University in Connecticut before pursuing his medical degree at Mount Sinai School of Medicine in New York. He then went on to train at Johns Hopkins for his urologic residency and Society of Urologic Oncology (SUO) fellowship. Dr. Kates has expertise in all areas of urologic oncology, with a particular emphasis on bladder and prostate cancer. With training in open, endoscopic, and robotic surgical approaches, Dr. Kates’ surgical philosophy is to assess the unique needs of each patient, and develop the right treatment plan for their malignancy. He is very hands on in his approach in the clinic and the operating room, and believes open communication with the patient, the patient’s family, and referring providers is key to ensuring a speedy recovery. As the clinical director of the bladder cancer multidisciplinary clinic, Dr. Kates works with the team at the Johns Hopkins Greenberg Bladder Cancer Institute to deliver a personalized approach to bladder cancer utilizing cutting edge precision medicine approaches. Dr. Kates’ research interests involve novel treatments for cancers of the urinary tract. Dr. Kates has authored more than 135 journal articles in the fields of bladder, prostate, and kidney cancer. He currently has a provisional patent for a novel intravesical chemotherapy developed with nano-engineer collaborators. Additionally, Dr. Kates has made important discoveries into the mechanism of action of intravesical BCG, the most common treatment for bladder cancer. He is the principal investigator on multiple trials, and is currently leading EA8212 BRIDGE, which is a randomized trial open in over 150 centers in the United States comparing BCG to GemDoce chemotherapy for early stage bladder cancer. To inquire about an appointment or make a referral, Dr. Kates can be contacted by phone (410) 614-0009. Dr. Kates is rated as an Elite provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Nephrectomy.
Chesapeake Urology Associates LLC
Rian Dickstein is an Urologist in Baltimore, Maryland. Dr. Dickstein is rated as an Elite provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Hydronephrosis, Ureteroscopy, and Nephrectomy. Dr. Dickstein is currently accepting new patients.
Medstar Medical Group Ii LLC
Lambros Stamatakis is an Urologist in Washington, Washington, D.c.. Dr. Stamatakis is rated as a Distinguished provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Nephrectomy, and Reconstructive Urology Surgery. Dr. Stamatakis is currently accepting new patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Acute CystitisDr. Kang isExperienced. Learn about Acute Cystitis.
- Bilateral HydronephrosisDr. Kang isExperienced. Learn about Bilateral Hydronephrosis.
- Bladder CancerDr. Kang isExperienced. Learn about Bladder Cancer.
- Bladder StonesDr. Kang isExperienced. Learn about Bladder Stones.
- BoilsDr. Kang isExperienced. Learn about Boils.
- CarbuncleDr. Kang isExperienced. Learn about Carbuncle.